Koers LENZ Therapeutics, Inc. OTC Markets
Aandelen
GRPH
US52635N1037
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 20,46 mln. 19,14 mln. | Marktkapitalisatie | 401 mln. 375 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -55 mln. -51,44 mln. | Nettowinst (verlies) 2025 * | -70 mln. -65,47 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 19,6 x |
K/w-verhouding 2024 * |
-7,19
x | K/w-verhouding 2025 * |
-6,46
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,31% |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.01% | 0 M€ | 0,00% | - | |
0.01% | 0 M€ | 0,00% | - | |
0.00% | 34 M€ | +2,14% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |